Description
CJC-1295 With DAC Technical Overview
CJC-1295 with Drug Affinity Complex (DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH).
The peptide includes structural modifications of the GHRH(1–29) sequence and a chemical group designed to interact with circulating albumin, extending systemic exposure.
Research has investigated CJC-1295 receptor-mediated growth hormone signaling and endocrine responses, including changes in circulating growth hormone and IGF-1 measurements.
Compound Specifications
| Property | Value |
|---|---|
| Compound Name | CJC-1295 With DAC |
| Classification | Modified GHRH analogue |
| Research Receptor | GHRH receptor (GHRHR) |
| Structural Feature | Drug Affinity Complex for albumin association |
| Related Sequence | Modified GHRH(1–29) |
| Vial Content | 5mg |
| Research Category | Endocrine Research |
Storage and Handling
- Follow manufacturer-recommended storage conditions.
- Protect from moisture and contamination.
- Use appropriate laboratory handling procedures.
Lyophilized Format
CJC-1295 may be supplied in lyophilized form. Stability depends on the preparation and chemical modifications.
Research Use Disclaimer
CJC-1295 is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.
Frequently Asked Questions
What Is CJC-1295 With DAC?
A modified GHRH analogue containing an albumin-binding chemical modification.
What Does DAC Mean?
Drug Affinity Complex.
What Receptor Does It Target?
The GHRH receptor.
Is CJC-1295 With DAC the Same as No DAC?
No. The DAC modification distinguishes the compounds.
Is It FDA-Approved?
No.
Research Overview
CJC-1295 was developed to investigate prolonged pharmacological activity of modified GHRH analogues.
GHRHR Signaling
Experimental investigations evaluate growth hormone-releasing hormone receptor activity.
Albumin Association
The DAC modification supports prolonged association with circulating albumin.
Growth Hormone Research
Human pharmacology studies investigated changes in GH and IGF-1 following CJC-1295 exposure.
Research Applications
| Research Area | In Vitro Application |
|---|---|
| GHRHR | Receptor signaling assays |
| Albumin Binding | Protein interaction research |
| Peptide Chemistry | DAC-modified peptide characterization |
References
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of Growth Hormone-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. View publication.
Certificate of Analysis (COA)
Documentation should verify the complete DAC-modified peptide structure, purity, and content. Peptide Lives.
Reviews
There are no reviews yet.